Please login to the form below

Not currently logged in
Email:
Password:

tumours

This page shows the latest tumours news and features for those working in and with pharma, biotech and healthcare.

Lilly’s Cyramza narrowly clears FDA adcomm vote for first-line NSCLC

Lilly’s Cyramza narrowly clears FDA adcomm vote for first-line NSCLC

Around 40% of patients with advanced HCC tumours express high levels of AFP – these tumours tend to be more aggressive than those with low AFP expression.

Latest news

More from news
Approximately 9 fully matching, plus 1,103 partially matching documents found.

Latest Intelligence

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    Moreover, they think there is scope to extend the use of the drug to breast cancer and other solid tumours in patients who express lower levels of the HER2 biomarker than ... knocked back by an FDA advisory committee in 2019 but still in development –

  • Evolution or revolution: the latest review of NICE methods Evolution or revolution: the latest review of NICE methods

    The specific issues of technologies, such as treatments developed to target tumours based on genetics and not their position within the body, is also included.

  • A snapshot of Crescendo Biologics A snapshot of Crescendo Biologics

    cancer. Crescendo’s lead programme is CB307, a novel, bispecific molecule that simultaneously binds to the CD137 (or ‘4-1BB’) receptor on T cells and PSMA protein on tumour cells. ... This molecule is designed for the treatment of prostate and

  • Leading AstraZeneca’s return to growth in Europe Leading AstraZeneca’s return to growth in Europe

    all the other tumour types in which it has already been approved or is pending approval. ... Approvals in BRCA-mutated pancreatic and prostate cancer are also expected in the near future, two tumour types where currently physicians aren’t accustomed to

  • Encouraging signs in biomarker R&D Encouraging signs in biomarker R&D

    Tumour mutational burden. TMB – or tumour mutational burden – is a measurement of mutations carried by tumour cells.

More from intelligence
Approximately 0 fully matching, plus 83 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 19 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 34 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Bedrock Group

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

The ALS patient journey
Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...
Equipping your medical affairs teams with solutions to navigate the healthcare landscape
Dr Tyler Ray, OPEN Health Medical Communications...
Protein degraders
Can protein degraders unlock ‘undruggable’ drug targets?
Exploring a new and exciting area of small-molecule drug discovery...

Infographics